Objective To investigate the efficacy and safety of perampanel (PER) add-on therapy in children with epilepsy of genetic etiology. Methods A retrospective analysis was conducted on the clinical data of 53 children who attended the Department of Neurology, Wuhan Children's Hospital, from November 2020 to April 2023. All children received PER add-on therapy and were diagnosed with epilepsy of genetic etiology based on whole-exome sequencing. The primary outcome measure was the proportion of children with a reduction in seizure frequency of ≥50% at month 12 of PER treatment (i.e., response rate), and the secondary outcome measures were response rates at months 3 and 6 of treatment. The influencing factors for the efficacy of PER add-on therapy in the treatment of epilepsy of genetic etiology were analyzed, and adverse events were recorded. Results The median follow-up duration was 13.10 months. After 12 months of follow-up, 42 children were included in the analysis, comprising 25 boys (60%) and 17 girls (40%). The median initial dose of PER was 1.5 (1.0, 2.0) mg/d, and the median maintenance dose was 4.0 (3.0, 8.0) mg/d. The response rates to PER at months 3, 6, and 12 of treatment were 61% (30/49), 54% (25/46), and 48% (20/42), respectively. No significant difference in the efficacy of PER was observed between children with mutations in genes encoding different protein functions (P>0.05). The most common adverse event reported was fatigue, observed in 3 children (6%). Conclusions PER add-on therapy demonstrates good efficacy and safety in children with epilepsy of genetic etiology. No influencing factors for the efficacy of PER have been identified to date.
Key words
Epilepsy /
Perampanel /
Add-on therapy /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Aaberg KM, Gunnes N, Bakken IJ, et al. Incidence and prevalence of childhood epilepsy: a nationwide cohort study[J]. Pediatrics, 2017, 139(5): e20163908. PMID: 28557750. DOI: 10.1542/peds.2016-3908.
2 阳文燕, 崔怡然, 马于岚, 等. 1990—2019年中国儿童及青少年癫痫疾病负担趋势研究[J]. 中国卫生统计, 2024, 41(2): 274-276. DOI: 10.11783/j.issn.1002-3674.2024.02.026.
3 Scala M, Bianchi A, Bisulli F, et al. Advances in genetic testing and optimization of clinical management in children and adults with epilepsy[J]. Expert Rev Neurother, 2020, 20(3): 251-269. PMID: 31941393. DOI: 10.1080/14737175.2020.1713101.
4 Symonds JD, Elliott KS, Shetty J, et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants[J]. Brain, 2021, 144(9): 2879-2891. PMID: 34687210. PMCID: PMC8557326. DOI: 10.1093/brain/awab162.
5 Sisodiya SM. Precision medicine and therapies of the future[J]. Epilepsia, 2021, 62Suppl 2(Suppl 2): S90-S105. PMID: 32776321. PMCID: PMC8432144. DOI: 10.1111/epi.16539.
6 Perversi F, Costa C, Labate A, et al. The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy[J]. Front Neurol, 2023, 14: 1182304. PMID: 37483446. PMCID: PMC10359664. DOI: 10.3389/fneur.2023.1182304.
7 Qu R, Dai Y, Qu X, et al. Use of perampanel in children with refractory epilepsy of genetic aetiology[J]. Epileptic Disord, 2022, 24(4): 687-695. PMID: 35770768. DOI: 10.1684/epd.2022.1443.
8 Turón-Vi?as E, Díaz-Gómez A, Coca E, et al. Long-term efficacy of perampanel in a child with dravet syndrome[J]. Child Neurol Open, 2021, 8: 2329048X211050711. PMID: 34692895. PMCID: PMC8532213. DOI: 10.1177/2329048X211050711.
9 Miao P, Zhu X, Jin W, et al. Efficacy of perampanel in pediatric epilepsy with known and presumed genetic etiology[J]. Ann Clin Transl Neurol, 2023, 10(8): 1374-1382. PMID: 37329172. PMCID: PMC10424658. DOI: 10.1002/acn3.51828.
10 Nissenkorn A, Kluger G, Schubert-Bast S, et al. Perampanel as precision therapy in rare genetic epilepsies[J]. Epilepsia, 2023, 64(4): 866-874. PMID: 36734057. DOI: 10.1111/epi.17530.
11 Elmardenly A, Aljehani Z, Tamim A, et al. Efficacy and safety of perampanel in children with drug-resistant focal-onset seizures: a retrospective review[J]. Children (Basel), 2023, 10(6): 1071. PMID: 37371302. PMCID: PMC10297347. DOI: 10.3390/children10061071.
12 Auvin S, Dozieres B, Ilea A, et al. Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome[J]. Epilepsy Behav, 2017, 74: 59-63. PMID: 28715780. DOI: 10.1016/j.yebeh.2017.05.036.
13 Zeng Q, Xia X, Jiang L, et al. Efficacy and safety of adjunctive perampanel treatment in pediatric patients with epilepsy aged 4-12 years: a real-world study[J]. J Neurol, 2024, 271(7): 4566-4576. PMID: 38717610. DOI: 10.1007/s00415-024-12416-y.
PDF(513 KB)
